Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

作者：Jean Addington, Lu Liu, Monica Chu, Karl Jungert, Nora Penzel, Ofer Pasternak, Emily K. Farina, Ricardo E. Carrión, Cheryl M. Corcoran, Vijay A. Mittal, Gregory P. Strauss, Alison R. Yung, Luis Alameda, Celso Arango, Owen Borders, Sylvain Bouix, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Rolando I Castillo-Passi, Eric Chen, Jimmy Choi, Michael Coleman, Philippe Conus, Covadonga M. Díaz‐Caneja, Lauren M. Ellman, Paolo Fusar‐Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Tina Kapur, Sinéad Kelly, Melissa Kerr, Matcheri S. Keshavan, Minah Kim, Sung‐Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Kathryn E. Lewandowski, Daniel Mamah, Patricia Marcy, Daniel H. Mathalon, Catalina Mourgues, Merete Nordentoft, Ángela Núñez, Godfrey D. Pearlson, Jesús Pérez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Johanna Seitz‐Holland, Jai Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Lauren Addamo, Kate Buccilli, Dominic Dwyer, Sophie Todd, Youngsun Cho, Clara Fontenau, Zailyn Tamayo, Carrie E. Bearden, John M. Kane, Patrick D. McGorry, René S. Kahn, Martha E. Shenton, Scott W Woods, Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby, Monica E Calkins · 发表于：Schizophrenia Bulletin Open · 年份：2025 · DOI：10.1093/schizbullopen/sgaf012 · 被引用次数：2 · 研究领域：Schizophrenia research and treatment、Tryptophan and brain disorders、Mental Health and Patient Involvement

Background: This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods: The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results: CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion: The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CH...